Conti D M, Backer V, Fokkens W, Gevaert P, Peters A, Scadding G K, Pavord I, Lau S, Wechsler M, Bertels X, Liva G, Doulaptsi M, Prokopakis E, Hellings P W
Allergy and Clinical Immunology Research Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
Escuela de Doctorado UAM, Centro de Estudios de Posgrado, Universidad Autónoma de Madrid, Calle Francisco Tomás y Valiente, Madrid, Spain.
Front Allergy. 2024 Dec 12;5:1517122. doi: 10.3389/falgy.2024.1517122. eCollection 2024.
The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized the first European Biologic Training Course (EBTC) in Brussels on 1st March 2024. The aim of this hybrid EBTC including both face-to-face and web-based participation was to address the educational needs of physicians dealing with asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) on the clinically relevant aspects of diagnosing and treatment with biologics. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via educational, research, and advocacy activities. The inclusive and multidisciplinary approach of EUFOREA was reflected in faculty coming from the paediatric, allergology, pulmonology, and Ear, Nose and Throat (ENT) speciality and from different continents, with more than 250 participants from over 30 countries in the first EBTC. The current report provides a comprehensive overview of key statements made by the faculty of the EBTC 2024, especially focusing on patient selection for a biologic drug, the communication with patients, the onset of biological treatment and the follow-up in routine clinical practice.
欧洲过敏与气道疾病研究与教育论坛（EUFOREA）于2024年3月1日在布鲁塞尔举办了首届欧洲生物制剂培训课程（EBTC）。这次混合式EBTC包括面对面和网络参与两种形式，其目的是满足处理哮喘和鼻息肉慢性鼻-鼻窦炎（CRSwNP）的医生在生物制剂诊断和治疗的临床相关方面的教育需求。EUFOREA是一个国际非营利组织，它联合了所有利益相关者，致力于通过教育、研究和宣传活动实施最佳患者护理，以降低慢性呼吸道疾病的患病率和负担。EUFOREA包容和多学科的方法体现在其教员来自儿科、过敏科、肺科以及耳鼻喉（ENT）专科，且来自不同的大陆，在首届EBTC中有来自30多个国家的250多名参与者。本报告全面概述了2024年EBTC教员发表的关键声明，尤其侧重于生物制剂药物的患者选择、与患者的沟通、生物治疗的开始以及常规临床实践中的随访。
